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Abstract
Dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2) is a member of dual-
specificity kinase family, which could phosphorylate both Ser/Thr and Tyr substrates. The
role of DYRK2 in human cancer remains controversial. For example, overexpression of
DYRK2 predicts a better survival in human non-small cell lung cancer. In contrast, amplifica-
tion of DYRK2 gene occurs in esophageal/lung adenocarcinoma, implying the role of
DYRK2 as a potential oncogene. However, its clinical role in colorectal cancer (CRC) has
not been explored. In this study, we analyzed the expression of DYRK2 from Oncomine
database and found that DYRK2 level is lower in primary or metastatic CRC compared to
adjacent normal colon tissue or non-metastatic CRC, respectively, in 6 colorectal carcinoma
data sets. The correlation between DYRK2 expression and clinical outcome in 181 CRC
patients was also investigated by real-time PCR and IHC. DYRK2 expression was signifi-
cantly down-regulated in colorectal cancer tissues compared with adjacent non-tumorous
tissues. Functional studies confirmed that DYRK2 inhibited cell invasion and migration in
both HCT116 and SW480 cells and functioned as a tumor suppressor in CRC cells. Further-
more, the lower DYRK2 levels were correlated with tumor sites (P = 0.023), advanced clini-
cal stages (P = 0.006) and shorter survival in the advanced clinical stages. Univariate and
multivariate analyses indicated that DYRK2 expression was an independent prognostic
factor (P < 0.001). Taking all, we concluded that DYRK2 a novel prognostic biomarker of
human colorectal cancer.
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Introduction
Dual-specificity tyrosine-phosphorylation-regulated kinase, including dual-specificity yak-
related kinases (DYRKs) represent a large family of dual-specificity kinase, which can phos-
phorylate both Ser/Thr and Tyr substrates. To date, at least seven DYRK family members have
been identified (DYRK1A, DYRK1B, DYRK1C, DYRK2, DYRK3, DYRK4A and DYRK4B) [1].
The DYRKs are evolutionarily conserved in their kinase domain, but differ from each other
in the N- and C-terminal regions. These kinase domains have several distinct amino-acid
sequences, including a DYRK homology (DH) box immediately preceding the kinase domain,
a YXY motif in the kinase-domain-activation loop between subdomains VII and VIII, an SSC
motif following sub domain VII, and conserved sequences HCDLKPEN and YXYIQSRFYR
(S/A) PE in subdomains VI and VIII [2].
Emerging evidences indicated that DYRKs are pleiotropic regulators of widespread cellular
functions including cell survival, cell differentiation, gene transcription and endocytosis [3].
DYRK1A/1B and DYRK3 may serve as protective kinases against apoptosis [4–6]. In specific
tissues, such as neurons, muscle and blood cells, DYRK1A/1B and DYRK3 also play a role dur-
ing cell differentiation [7–9]. Conversely, DYRK2 behaves as a proapoptotic kinase through
phosphorylation of p53 at S46 which promotes its apoptotic activity [10]. Down-regulation of
DYRK2 could also induce a G2/M arrest [11].
Abundant studies have demonstrated that DYRKs are related to human diseases. For exam-
ple, increased expression of DYRK1A occurred in Down syndrome [12], as well as different
types of solid tumors [13]. Interestingly, the role of DYRK2 in human cancer remains contro-
versial. Yamashita et al reported that DYRK2 overexpression predicted a better survival in
human non-small cell lung cancer, implying a tumor suppressor role [14]. Likewise, higher
DYRK2 expression in breast cancer and pulmonary adenocarcinoma may enhance survival
[15, 16]. And yet others have noted amplification and overexpression of DYRK2 in esophageal
and lung adenocarcinoma, as well as gastric stromal tumor, suggesting that DYRK2 can behave
as a potential oncogene [17–19], although the protein levels of the gene were not examined.
In this study, we investigated the prognostic significance of DYRK2 expression of in 181
archived CRC samples. Our study offers the first piece of evidence that shows the significant
correlation between lower protein level of DYRK2 and tumor location in rectum, advanced
tumor stage and unfavorable prognosis in clinical stage III and IV CRC patients. This study
also confirmed that decreased expression of DYRK2 happened in rectal cancer more often than
in colon cancer.
Methods
Ethics
The use of tissues for this study has been approved by the Ethics Committee of Sun Yat-Sen
Memorial Hospital, Sun Yat-Sen University. At the time of initial diagnosis, all patients had
provided written consent in the sense that their tumor samples could be used for the investiga-
tion's purpose.
Oncomine databases
The Oncomine Platform, from web applications to translational bioinformatics services, pro-
vides solutions for individual researchers and multinational companies, with robust, peer-
reviewed analysis methods and a powerful set of analysis functions that compute gene expres-
sion signatures, clusters, and gene-set modules, automatically extracting biological insights from
the data. At present, the Oncomine has been contained by about 48 million gene expression
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measurements 65 sets of gene expression data set for use by researchers [20]. The detail state-
ments for 6 colorectal carcinoma data sets information have been listed in the Table 1.
RNA extraction, reverse transcription and real-time PCR
Total RNAs from 16 pairs of tumor tissues and non-tumorous tissues were extracted by using
the miRNeasy Mini Kit (Qiagen #217004) according to the manufacturer’s instruction. The clini-
copathologic information of the 16 CRC samples was described in Table 2. Real-time PCR was
performed according to standard methods as described previously [25]. GAPDH was used as an
internal control. Sequences of the primers for qPCR were listed as follows, DYRK2 sense: 5’
CCTGAACAAGCAATGAAGCA; DYRK2 antisense: 5’ GGTCATCATCATAGCCACCA; GAPDH
sense: 5’AGAAGGCTGGGGCTCATTTG; GAPDH antisense: 5’ GACAAGCTTCCCGTTCTCAG.
Tumor specimens and patient data
181 paraffin-embedded archived samples of CRC were used in immunohistochemistry, includ-
ing 99 samples with adjacent non-tumorous (ANT) tissues. All these samples were derived
from initial surgery without either preoperative chemotherapy or radiotherapy at Sun Yat-Sen
Memorial Hospital between 2002 and 2009. TNM staging and clinicopathologic classification
were determined according to the National Comprehensive Cancer Network (NCCN) classifi-
cation. The clinicopathologic information of the 181 CRC samples was described in Table 3.
Overall survival (OS) was defined as the interval between the date of surgery and the date of
death or the last known follow up. Additionally, six pairs of matched tumor samples and adja-
cent non-cancerous tissues (collected immediately after surgery and stored at −80°C were used
for real-time PCR analysis.
Cell culture and RNA interference
Human colon cancer cell lines HCT116 and SW480 (purchased from ATCC) were maintained
in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) supplemented with 10% fetal
bovine serum (HyClone), 1 mM glutamine and 100 U/ml each of penicillin and streptomycin.
Table 1. The detail information of the six Oncomine datasets.
Dataset Name Study Description Array Types Experiment
Type
Gaedcke Colorectal
Dataset
Sixty-five (65) rectal adenocarcinomas and their paired normal rectal
mucosa samples were analyzed. [20]
Agilent Human Genome 44K,Measured
19,189 genes, 41,000 reporters.
mRNA
Skrzypczak
Colorectal 2 Dataset
Forty (40) microdissected samples (5 replicates each of 8 types of
epithelial or mucosa cells from tumor or normal tissues) were analyzed.
[21]
Human Genome U133 Plus 2.0 Array,
Measured 19,574 genes, 54,675
reporters.
mRNA
Kaiser Colon
Dataset
One hundred (100) colorectal carcinoma and 5 normal colon samples
were analyzed. [22]
Human Genome U133 Plus 2.0 Array,
Measured 19,574 genes, 54,675
reporters.
mRNA
TCGA Colorectal
Dataset
One hundred forty-six (146) colon adenocarcinoma, 69 rectal
adenocarcinoma, 19 paired normal colon, and 3 paired normal rectum
tissue samples were analyzed. [23]
Platform not pre-defined in Oncomine,
Measured 20,423 genes, 111,123
reporters.
mRNA
Bittner Colon
Dataset
Three-hundred seventy-three (373) colorectal carcinoma samples were
analyzed.
Human Genome U133 Plus 2.0 Array,
Measured 19,574 genes, 54,675
reporters.
mRNA
Ki Colon Dataset One hundred and three (103) matched samples from 27 colorectal
cancer patients were analyzed. [24]
Platform not pre-defined in Oncomine,
Measured 9,256 genes, 15,783
reporters.
mRNA
doi:10.1371/journal.pone.0159954.t001
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The sequence of the DYRK2 siRNA has been reported [10, 27]. The sequences of oligonucleo-
tides1, 2, 3, 4 and 5 targeting DYRK2 mRNA, are Si#1: GGUGCUAUCACAUCU AUAU; Si#2: GGA
CAGTGCTCACGACACAACCAAA; Si#3: CCACGATCACGTGGCTTACAGG TAT; Si#4: GCCA
GGTATGGCATGCCCATTGATA; Si#5: GGGTAGAAGCGGTATTAAA, respectively. These siRNAs
were synthesized by GenePharma. Approximately 2 × 105 cells per well were seeded in a 6-well
tissue culture dish on the day before transfection. Transfection of 50 nmol siRNAs was per-
formed according to the manufacturer’s instructions by using the LipofectamineTM RNAiMAX
transfection reagent (Invitrogen).
Western blotting and antibodies
Western blotting was performed as described previously [20]. Briefly, cells were lysed in
MCLB, and clarified lysates were resolved by SDS-PAGE and transferred to PVDF membranes
for western blotting by using ECL detection reagents (Beyotime Co. Haimen, Jiangsu, China).
Antibodies against E-cadherin (#3195), N-cadherin (#13116) and Vimentin (5741) were from
Cell Signaling Technology. Antibodies against DYRK2 (SC-130743), Fibronectin (sc-9068) and
GAPDH (SC-25778) were from Santa Cruz Biotechnology.
Table 2. The clinicopathologic features of the 16 CRC samples.
Number of cases (%)
Gender
Male 10 (62.5)
Female 6 (37.5)
Age (years)
 50 4 (25.0)
> 50 12 (75.0)
Location
Colon 9 (56.2)
Rectal 7 (43.8)
Clinical Stage
II 3(18.7)
III 7(43.8)
IV 6 (37.5)
T classification
T1 2(12.5)
T2 4 (25.0)
T3 6 (37.5)
T4 4(25.0)
N classification
N0 4 (25.0)
N1 7(43.8)
N2 5 (31.2)
M classification
M0 10(62.5)
M1 6 (37.5)
Pathologic Type
Adenocarcinoma 13 (81.2)
Mucinous Adenocarcinoma 3 (18.8)
doi:10.1371/journal.pone.0159954.t002
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Cell cycle analysis
Cells were harvested, washed with PBS, and fixed with ice-cold 70% ethanol overnight. Cells
were then washed in PBS and treated for 20 min at 37°C with RNase A (200 lg/ml), followed by
incubation with propidium iodide (25 lg/ml), and analyzed by flow cytometry by using a
Cytomics FC 500 flow cytometer (Beckman). The data were analyzed by using Multicycle AV
for Windows (Beckman).
Wound-healing and transwell assays
Cells were trypsinized and seeded equally into 6-well plates to grow to almost full confluence in
24 hours, followed by nonserum starvation for another 24 hours. The cell monolayer was then
scratched with a sterile 100 ml pipette tip. After scratching, the cells were washed with PBS and
Table 3. Clinicopathological characteristics and DYRK2 expression of 181 patient samples of CRC.
Number of cases (%)
Gender
Male 122 (67.4)
Female 59 (32.6)
Age (years)
 50 64 (35.4)
> 50 117 (64.6)
Location
Colon 82 (45.3)
Rectal 99 (54.7)
Clinical Stage
I 35 (19.3)
II 41 (22.7)
III 48 (26.5)
IV 57 (31.5)
T classification
T1 14 (7.7)
T2 30 (16.6)
T3 86 (47.5)
T4 51 (28.2)
N classification
N0 85 (47.0)
N1 55 (30.4)
N2 41 (22.7)
M classification
M0 124 (68.5)
M1 57 (31.5)
Pathologic Differentiation
Poor 38 (21.0)
Moderate 129 (71.3)
Well 14 (7.7)
Expression of DYRK2
Low expression 94 (51.9)
High expression 87 (48.1)
doi:10.1371/journal.pone.0159954.t003
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then cultured with a serum-free medium. Cell migration images were captured at time points
of 0 h, 24 h and 48 h by an inverted microscope (100X).
For the transwell migration assay, 1.5×105 cells in 200 μl of serum-free DMEM were added
to the cell culture inserts with an 8-μmmicroporous filter without extracellular matrix coating
(Becton Dickinson Labware, Bedford, MA). The DMEMmedium containing 10% FBS was
added to the bottom chamber. After 36 hours of incubation, the cells in the lower surface of the
filter were fixed and stained prior to microscopic examination. The number of migrated cells
in three random optical fields (100 X) for each filter from triplicate filters was averaged. For the
invasion assay, the inserts of the chambers to which the cells were seeded were coated with
Matrigel (Becton Dickinson Labware, Bedford, MA). The number of invading cells in three
random optical fields (100X) for each filter from triplicate inserts was averaged.
Immunohistochemistry (IHC) and scoring
Immunohistochemistry was used to study the altered protein expression of DYRK2 in 181
CRC tissues. The procedure was described previously [26]. Briefly, paraffin-embedded tissue
blocks were cut at 4 μm thickness before staining. The tissue sections were then deparaffinized
at 60°C for 2 hours and rehydrated by two and three changes of xylene and ethanol, respec-
tively. Endogenous peroxidase activity was quenched by incubating with 3% hydrogen perox-
ide for 30 minutes at room temperature after deparaffinization. Then, antigen retrieval was
performed at 121°C for 10 minutes in an autoclave with citrate buffer. Nonspecific binding was
blocked by incubating sections with 10% goat serum for 30 minutes at room temperature. The
sections were then incubated with a rabbit anti-DYRK2 antibody (1:100; Santa Cruz) overnight
at 4°C. After washinged, tissue sections were incubated with biotinylated anti-rabbit secondary
antibody for 20 minutes, followed by further incubation with streptavidin-horseradish peroxi-
dase complex. Finally, the sections were developed with diaminobenzidine tetrahydrochloride
(DAB) and further counterstained with hematoxylin. The degree of the immunostaining sec-
tions was determined by two researchers. One score for the percent of positive cells was set
as 10% = 0,>10% to 25% = 1,>25% to 50% = 2,>50% to 75% = 3,>75% = 4.
Another score for the intensity of cytoplasm staining was set as negative = 0, weak = 1, moder-
ate = 2, or strong = 3. The two scores above were then calculated by multiplying as the final
score. Low DYRK2 expression was defined as a final score of 4 and 6 as a high DYRK2
expression.
Statistical analysis
All statistical analysis was carried out by using the SPSS 16.0 statistical software package (SPSS
Inc., Chicago, IL). Difference of DYRK2 expression between tumor tissues and matched ANT
tissues was analyzed by the Wilcoxon signed rank test. Correlation between DYRK2 expression
and clinical parameters was analyzed by using the Pearson’s chi-squared test. Survival curves
were plotted by the Kaplan-Meier method and compared by the log-rank test. Survival data
were evaluated by using univariate and multivariate Cox regression analyses. A two-sided P-
value of less than 0.05 was considered to be statistically significant.
Results
DYRK2 expression analysis of Oncomine database
The mRNA levels of kinase from Oncomine databases were analyzed. In CRC, DYRK2 level
was found lower in primary or metastatic CRC compared with adjacent normal colon tissues
or non-metastatic CRC in all 6 colorectal carcinoma data sets respectively. Specifically, In 65
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PLOS ONE | DOI:10.1371/journal.pone.0159954 August 17, 2016 6 / 18
pairs of normal rectum and primary rectal adenocarcinoma, the level of DYRK2 is lower in
cancer tissue compared to paired adjacent normal tissues significantly (Fig 1A). Several other
data sets also indicated the similar results (Fig 1B, 1C and 1D). Furthermore, we found that the
high grade of CRC and metastatic CRC have less expression of DYRK2 compared with low
grades and non-metastatic CRC (Fig 2).
Decreased expression of DYRK2 in colorectal cancer tissues
To investigate the role of DYRK2 in tumorigenesis, the expression of DYRK2 in both mRNA
and protein levels were evaluated in CRC samples. Decreased expression of DYRK2 mRNA
was observed in 16 CRC samples compared with matching ANT samples as observed by real-
time PCR (Fig 3). The detail clinicopathologic features listed in the Table 2. We further exam-
ined DYRK2 expression by IHC in 181 paraffin-embedded CRC samples, including 99
matched ANT tissues. DYRK2 expression was substantially down regulated in the tumor
Fig 1. mRNA expression of DYRK2 is lower in CRC compared to the normal colon/rectum. A. Gaedcke's colorectal carcinoma data set: paired
normal colon vs paired CRC; B. Skrzypczak's colorectal carcinoma data set: Normal colon vs colorectal adenocarcinoma and colorectal carcinoma; C.
Kaiser's colorectal carcinoma data set: normal colon vs different types of CRC; D. TCGA colorectal carcinoma data set: normal colon and rectum vs
different type of CRC.
doi:10.1371/journal.pone.0159954.g001
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Fig 2. mRNA expression of DYRK2 is lower in high grade andmetastatic CRC compared to low grade and non-metastatic CRC. A. Bittner's
colorectal carcinoma data set: low grade CRC vs high grade CRC; B. Bittner's colorectal carcinoma data set: non-metastatic CRC vs metastatic CRC; C.
Ki's colorectal carcinoma data set: adjacent normal colon vs primary CRC without liver metastatic CRC vs primary CRC with liver metastatic CRC and
secondary CRCmetastasis at liver; D. Ki's colorectal carcinoma data set: paired primary CRC with liver metastatic CRC vs paired secondary CRC
metastasis at liver.
doi:10.1371/journal.pone.0159954.g002
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tissues compared with the ANT tissues (Fig 4B, P< 0.001, Wilcoxon signed rank test), and 5
pairs of the representative slides were shown in Fig 4C, the clinicopathological characteristics
of 5 patients were shown in S1 Table.
DYRK2 inhibits the proliferation, cell migration and invasion of colorectal
cancer cells in vitro
To confirm the role of DYRK2 in CRC progression, we further analyzed the effect of DYRK2
depletion on cell cycle progression. The depletion of DYRK2 caused a significant decrease in
the G1 population, and yet an increase in the S-phase cell fractions in both HCT116 and
SW480 cells when compared with control cells (Fig 5A and 5B). DYRK2 was reported to be not
only associated with cancer cell growth but also with cancer metastasis (27, 28). Therefore, we
also examined the effect of DYRK2 depletion on CRC metastasis related markers. The western
blot assays revealed that the expression of the mesenchymal markers N-cadherin, Vimentin,
and Fibronectin, were significantly upregulated, while the epithelial marker E-cadherin was sig-
nificantly declined upon transient transfection with DYRK2 siRNA (Fig 5C). Furthermore, we
evaluated the effect of DYRK2 on CRC cells migration and invasion using wound-healing
transwell assays. As shown in Fig 5D and 5E, the cell's ability of wound healing was dramati-
cally enhanced after the depletion of endogenous DYRK2 in HCT116 and SW480 cells.
Likewise, the transwell assays showed that the abilities of migration and invasion were also dra-
matically enhanced by knocking down DYRK2 (Fig 5F and 5G). Taken together, these data
confirmed that DYRK2 inhibited cell proliferation, invasion and migration in both HCT116
and SW480 cells and functioned as a tumor suppressor in CRC cells.
Fig 3. Decreased expression of DYRK2mRNA in colorectal cancer tissues.Real-time PCR analysis of
DYRK2mRNA expression in sixteen primary colon cancer tissues (T) and adjacent non-cancerous tissues
(ANT) paired from the same patient.
doi:10.1371/journal.pone.0159954.g003
Low Expression of DYRK2 in Colorectal Cancer
PLOS ONE | DOI:10.1371/journal.pone.0159954 August 17, 2016 9 / 18
Fig 4. Decreased expression of DYRK2 in paraffin-embedded colorectal cancer tissues and advanced colorectal cancer. A,
DYRK2 protein expressed in adjacent non-cancerous tissue (ANT) and colorectal cancer tissue (T) by IHC analysis. B, Quantitative
analysis of DYRK2 expression in primary colorectal tumors and adjacent non-cancerous tissues (ANT) by IHC analysis (Wilcoxon
signed rank test, n = 99, P < 0.001). C, Immuno-staining of DYRK2 in five pairs of representative colorectal tumor tissues (T) with
adjacent non-cancerous tissues (ANT). D, Representative IHC analyses of DYRK2 expression at different clinical stages, two
magnifications (100X and 200X).
doi:10.1371/journal.pone.0159954.g004
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Fig 5. DYRK2 inhibits the proliferation, cell migration and invasion of colorectal cancer cells in vitro. A, B:
The effect of DYRK2 depletion on the cell cycle. Experiments were performed in triplicate. C: Western blot analysis
of E-cadherin, N-cadherin, Fibronectin and Vimentin expression in the indicated treatment of the CRC cell lines. D,
E: The cell's ability of wound gap closure was dramatically enhanced by knocking down DYRK2 both in HCT116
and SW480 cells. F, G: Migratory and invasive abilities of the indicated cell lines in vitro was measured by the
Low Expression of DYRK2 in Colorectal Cancer
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Correlation between DYRK2 expression and clinicopathologic features
of CRC
Clinical characteristics of CRC included 35 cases of clinical stage I (19.3%), 41 cases of clinical
stage II (22.7%), 48 cases of clinical stage III (26.5%), and 57 cases of clinical stage IV (31.5%)
CRC. 87 of total 181 CRC cases (48.1%) highly expressed DYRK2; 94 cases (51.9%) had low
expression of DYRK2 (Table 3).
A strong correlation occurred between DYRK2 expression (determined by using IHC stain-
ing), and clinicopathologic characteristics of these CRC patients, including tumor site (P = 0.023),
clinical stage (P = 0.006), Nodal (N) classification (P = 0.017), Metastasis (M) classification
(P = 0.004), and mortality (P< 0.001) (Table 4). In contrast, DYRK2 expression did not correlate
with gender, age and tumor differentiations (Table 4). Representative IHC stained slides showed
the correlation of DYRK2 expression with clinical stages (Fig 4D).
Association between DYRK2 expression and patient survival
A clear positive correlation existed between DYRK2 expression and the overall survival of
patients. Lower DYRK2 expression correlated with a shorter overall survival time (OS) (median
OS: 44.0 months) compared with higher DYRK2 expression (median OS: not reached up to
77.0 months) (Fig 6A, P< 0.001). The overall two-, three-, and five-year accumulative survival
Transwell assay as described in “Materials and methods”. Bars correspond to mean+ standard error, with a P value
calculated by using Student’s t-test. *P<0.05, **P<0.001.
doi:10.1371/journal.pone.0159954.g005
Table 4. Correlation between DYRK2 expression and clinicopathological characteristics of CRC patients.
Characteristics DYRK2 Chi-square Test P-value
Low or none High
No. cases (%) No. cases (%)
Gender Female 32 (34.0) 27 (31.0) 0.751
Male 62 (66.0) 60 (69.0)
Age (years)  50 35 (37.2) 29 (33.3) 0.642
> 50 59 (66.9) 58 (66.7)
Location colon 35 (46.9) 47 (45.6) 0.023
rectal 59 (53.1) 40 (54.4)
Clinical Stage I 12 (12.8) 23 (26.4) 0.006
II 17 (18.1) 24 (27.6)
III 26 (27.6) 22 (25.3)
IV 39 (41.5) 18 (20.7)
T classification T1+T2 18 (19.1) 26 (29.9) 0.118
T3+T4 76 (80.9) 61 (70.1)
N classification No 36 (38.3) 49 (56.3) 0.017
Yes 58 (61.7) 38 (43.7)
M classification M0 55 (58.5) 69 (79.3) 0.004
M1 39 (41.5) 18 (20.7)
Pathologic Differentiation Poor 22 (23.4) 16 (18.4) 0.365
Moderate 67 (71.3) 62 (71.3)
Well 5 (5.3) 9 (10.3)
Dead 56 (59.6) 21 (24.1)
doi:10.1371/journal.pone.0159954.t004
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rates of patients with higher DYRK2 expression were 81.4%, 77.4%, and 75.4%, respectively.
For patients with lower DYRK2 expression, the rates were 77.4%, 65.6%, and 44.3%, respec-
tively (Fig 6A). Furthermore, a significant correlation of DYRK2 expression with the OS was
found in the advanced clinical stages (stage III and IV) (Fig 6D, P = 0.039 (stage III); P = 0.004
(stage IV)). Moreover, Cox regression revealed that DYRK2 expression was an independent
prognostic factor for CRC patients, as well as N classification, M classification and pathologic
differentiation (Table 5).
Discussion
In recent years, the incidences of CRC have rapidly increased and become the second leading
cause of cancer death in China [27]. Although the clinical treatment of CRC has made great
Fig 6. Kaplan-Meier curves with univariate analyses (log-rank) for patients with low DYRK2 expression (dotted line) versus
high DYRK2 expression (bold line). A, Overall survival of patients (clinical stages I-IV) with either low or high DYRK2 expression.
B, Overall survival of patients (clinical stages I-II) with either low or high DYRK2 expression. C-D, Overall survival of patients (clinical
stages III (C) and IV (D)) with either low or high DYRK2 expression.
doi:10.1371/journal.pone.0159954.g006
Low Expression of DYRK2 in Colorectal Cancer
PLOS ONE | DOI:10.1371/journal.pone.0159954 August 17, 2016 13 / 18
progress, the clinical outcome of advanced CRC is still poor [28]. TNM classification remains
the “gold-standard” prognostic measure of this disease [29]. Sadly, disease-free and overall sur-
vival data still vary even on the same TNM stage. Apparently, better prognostic indexes are
urgently needed to guide therapy and benefit patients.
Protein phosphorylation is a key post-translational modification. In eukaryotes, protein
kinases are pivotal enzymes regulating a broad spectrum basic cellular processes by providing a
phosphate to substrates [30]. The dual-specificity tyrosine-regulated kinases (DYRKs) belong
to the CMGC protein kinases super family and were found to be pleiotropic regulators of cellu-
lar functions [3, 31]. DYRK2 behaves as a tumor suppressor in many human cancers. It
empowers p53 to induce apoptosis in response to DNA damage via the phosphorylation of Ser
46. Silencing DYRK2 function attenuates (adriamycin) -induced apoptosis [10]. Paradoxically,
DYRK2 can induce cell apoptosis in a p53-independent manner [10]. Studies of Taira et.al sug-
gested that DYRK2 regulated tumor progression in vivo an in vitro through the modulation of
c-Jun and c-Myc. The knockdown of DYRK2 shortened the G1 phase and accelerated cell pro-
liferation due to the escape of c-Jun and c-Myc from ubiquitination-mediated degradation
[32]. Besides, the knockdown of DYRK2 promoted Epithelial–mesenchymal transition (EMT)
and cancer invasion in human breast cancer cells [33]. In our study, we examined the effect of
DYRK2 invasion on CRC and revealed that the same phenomena. While DYRK2 was depleted,
the invasion ability of the CRC cell line SW480 and HCT116 were upgraded (Fig 5A, 5B and
5C). Furthermore, DYRK2 on CRC cells’migration ability of wound healing was dramatically
enhanced after the depletion of endogenous DYRK2 in HCT116 and SW480 cells (Fig 5D and
5E). Taken together, these data confirmed that DYRK2 inhibited cell invasion and migration in
both HCT116 and SW480 cells and functioned as a tumor suppressor in CRC cells. Moreover,
patients with DYRK2-positive tumors in recurrent non-small cell lung cancer has substantially
benefited from chemotherapy as compared with those with DYRK2-negative tumors [14]. This
Table 5. Univariate andmultivariate analysis of various prognostic parameters in patients with CRC Cox-regression analysis.
Variables Univariate analysis Multivariate analysis
No. P value Hazard Ratio 95% CI P value
DYRK2
low expression 94 <0.001 0.336 0.200–0.564 <0.001
high expression 87
T classification
T1 14 <0.001 1.043 0.750–1.452 0.801
T2 30
T3 86
T4 51
N classification
N0 85 <0.001 1.609 1.174–2.204 0.003
N1 55
N2 41
M classification
M0 124 <0.001 8.276 4.600–14.888 <0.001
M1 57
Differentiation
Poor 38 0.559 0.63 0.418–0.952 0.028
Moderate 129
Well 14
doi:10.1371/journal.pone.0159954.t005
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is consistent with our results that showed a relative favorable survival in patients with higher
expression of DYRK2 in clinical stage IV CRC (Fig 6D).
Our current study presented the first piece of evidence that DYRK2 was down regulated in
colon cancer at both transcriptional and translational levels. Real-time PCR by using 16 pairs
of human colorectal cancer tissues showed the down-expression of DYRK2 mRNA compared
with matching adjacent non-tumorous tissues (Fig 3, P< 0.001, paired t test). Accordingly,
IHC analysis showed down expression of DYRK2 protein in 99 CRC tissues compared with
matching adjacent non-tumorous tissues (Fig 4B, P< 0.001, Wilcoxon signed rank test).
Lower protein levels of DYRK2 significantly correlated with tumor location in rectum,
advanced tumor stage and unfavorable prognosis in clinical stage III and IV CRC patients.
Notably, the prognostic value of tumor site in CRC remains controversial. Some studies
revealed that survival of rectal cancer was worse than colon cancer [34], while others found the
opposite [35]. Leicester et al reported that CRC and normal childhood colorectal samples have
similar behavior in increased proliferation and decreased apoptosis with a significantly lower
expression of DYRK2 compared to healthy colonic mucosa from adults [36]. In our study, all
samples are from adult patients. Interestingly, our current study observed more cases of
decreased expression of DYRK2 in rectal cancer than in colon cancer (Table 4, P = 0.023).
Remarkably, multivariate analysis implied DYRK2 as an independent prognostic factor of sur-
vival in CRC patients.
Conclusions
In conclusion, our study revealed that the dual-specificity tyrosine-phosphorylation-regulated
kinase DYRK2 behaves as a tumor suppressor in the CRC Function tests confirmed that
DYRK2 inhibited cell proliferation, invasion and migration in both HCT116 and SW480 cells
and functioned as a tumor suppressor in CRC cells. The assessment of DYRK2 expression by
IHC at diagnosis may help guide therapeutic decisions. DYRK2 expression was highly associ-
ated with clinical stages, N classification and an M classification of CRC. Patients with reduced
DYRK2 expression had a shorter OS, and acted as an independent prognostic factor.
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